Cancer Monoclonal Antibodies Market, 2012 to 2023
Cancer monoclonal antibodies market: A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.
Cancer Monoclonal Antibodies Market Outline
The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.
Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel
Base on application, cancer monoclonal antibodies market is segmented into
Breast Cancer
Blood Cancer
Liver Cancer
Brain cancer
Colorectal Cancer
Others
Based on type of antibody, cancer monoclonal antibodies market is segmented into
Murine Antibodies
Humanized Antibodies
Chimeric Antibodies
Based on conjugation, cancer monoclonal antibodies market is segmented into
Immunocytokines
Immunoliposome
Radioimmunotherapy
Antibody Directed Enzyme Prodrug Therapy(ADEPT)
Based on distribution channel, cancer monoclonal antibodies market segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.
Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.
Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.
In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma
In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer
Cancer Monoclonal Antibodies Market Outline
The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.
Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel
Base on application, cancer monoclonal antibodies market is segmented into
Breast Cancer
Blood Cancer
Liver Cancer
Brain cancer
Colorectal Cancer
Others
Based on type of antibody, cancer monoclonal antibodies market is segmented into
Murine Antibodies
Humanized Antibodies
Chimeric Antibodies
Based on conjugation, cancer monoclonal antibodies market is segmented into
Immunocytokines
Immunoliposome
Radioimmunotherapy
Antibody Directed Enzyme Prodrug Therapy(ADEPT)
Based on distribution channel, cancer monoclonal antibodies market segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.
Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.
Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.
In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma
In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer
1. EXECUTIVE SUMMARY
2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET INTRODUCTION
2.1. Global Cancer Monoclonal Antibodies Market – Taxonomy
2.2. Global Cancer Monoclonal Antibodies Market –Definitions
2.2.1. Application
2.2.2. Type of Antibody
2.2.3. Conjugation
2.2.4. End-User
3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Monoclonal Antibodies Market Dynamics – Factors Impact Analysis
3.6. Global Cancer Monoclonal Antibodies Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Breast Cancer
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Blood Cancer
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Liver Cancer
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Brain cancer
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Colorectal Cancer
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY TYPE OF ANTIBODY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Murine Antibodies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Humanized Antibodies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Chimeric Antibodies
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY CONJUGATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Immunocytokines
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Immunoliposome
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Radioimmunotherapy
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Breast Cancer
10.1.2. Blood Cancer
10.1.3. Liver Cancer
10.1.4. Brain cancer
10.1.5. Colorectal Cancer
10.1.6. Others
10.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Murine Antibodies
10.2.2. Humanized Antibodies
10.2.3. Chimeric Antibodies
10.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Immunocytokines
10.3.2. Immunoliposome
10.3.3. Radioimmunotherapy
10.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Cancer Monoclonal Antibodies Market Dynamics – Trends
11. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Breast Cancer
11.1.2. Blood Cancer
11.1.3. Liver Cancer
11.1.4. Brain cancer
11.1.5. Colorectal Cancer
11.1.6. Others
11.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Murine Antibodies
11.2.2. Humanized Antibodies
11.2.3. Chimeric Antibodies
11.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Immunocytokines
11.3.2. Immunoliposome
11.3.3. Radioimmunotherapy
11.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends
12. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Breast Cancer
12.1.2. Blood Cancer
12.1.3. Liver Cancer
12.1.4. Brain cancer
12.1.5. Colorectal Cancer
12.1.6. Others
12.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Murine Antibodies
12.2.2. Humanized Antibodies
12.2.3. Chimeric Antibodies
12.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Immunocytokines
12.3.2. Immunoliposome
12.3.3. Radioimmunotherapy
12.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
12.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends
13. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Breast Cancer
13.1.2. Blood Cancer
13.1.3. Liver Cancer
13.1.4. Brain cancer
13.1.5. Colorectal Cancer
13.1.6. Others
13.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Murine Antibodies
13.2.2. Humanized Antibodies
13.2.3. Chimeric Antibodies
13.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Immunocytokines
13.3.2. Immunoliposome
13.3.3. Radioimmunotherapy
13.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Cancer Monoclonal Antibodies Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Breast Cancer
14.1.2. Blood Cancer
14.1.3. Liver Cancer
14.1.4. Brain cancer
14.1.5. Colorectal Cancer
14.1.6. Others
14.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Murine Antibodies
14.2.2. Humanized Antibodies
14.2.3. Chimeric Antibodies
14.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Immunocytokines
14.3.2. Immunoliposome
14.3.3. Radioimmunotherapy
14.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Cancer Monoclonal Antibodies Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Merck & Co. Inc. (U.S.)
15.2.2. F. Hoffmann-La Roche AG (Switzerland)
15.2.3. Spectrum Pharmaceuticals (U.S.)
15.2.4. Eli Lilly and Company (U.S.)
15.2.5. Amgen Inc. (U.S.)
15.2.6. Bristol-Meyer Squibb (U.S.)
15.2.7. Sanofi (France)
15.2.8. AstraZeneca (U.K.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET INTRODUCTION
2.1. Global Cancer Monoclonal Antibodies Market – Taxonomy
2.2. Global Cancer Monoclonal Antibodies Market –Definitions
2.2.1. Application
2.2.2. Type of Antibody
2.2.3. Conjugation
2.2.4. End-User
3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Monoclonal Antibodies Market Dynamics – Factors Impact Analysis
3.6. Global Cancer Monoclonal Antibodies Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Breast Cancer
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Blood Cancer
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Liver Cancer
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Brain cancer
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Colorectal Cancer
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY TYPE OF ANTIBODY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Murine Antibodies
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Humanized Antibodies
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Chimeric Antibodies
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY CONJUGATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Immunocytokines
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Immunoliposome
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Radioimmunotherapy
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Breast Cancer
10.1.2. Blood Cancer
10.1.3. Liver Cancer
10.1.4. Brain cancer
10.1.5. Colorectal Cancer
10.1.6. Others
10.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Murine Antibodies
10.2.2. Humanized Antibodies
10.2.3. Chimeric Antibodies
10.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Immunocytokines
10.3.2. Immunoliposome
10.3.3. Radioimmunotherapy
10.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Cancer Monoclonal Antibodies Market Dynamics – Trends
11. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Breast Cancer
11.1.2. Blood Cancer
11.1.3. Liver Cancer
11.1.4. Brain cancer
11.1.5. Colorectal Cancer
11.1.6. Others
11.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Murine Antibodies
11.2.2. Humanized Antibodies
11.2.3. Chimeric Antibodies
11.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Immunocytokines
11.3.2. Immunoliposome
11.3.3. Radioimmunotherapy
11.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends
12. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Breast Cancer
12.1.2. Blood Cancer
12.1.3. Liver Cancer
12.1.4. Brain cancer
12.1.5. Colorectal Cancer
12.1.6. Others
12.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Murine Antibodies
12.2.2. Humanized Antibodies
12.2.3. Chimeric Antibodies
12.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Immunocytokines
12.3.2. Immunoliposome
12.3.3. Radioimmunotherapy
12.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
12.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends
13. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Breast Cancer
13.1.2. Blood Cancer
13.1.3. Liver Cancer
13.1.4. Brain cancer
13.1.5. Colorectal Cancer
13.1.6. Others
13.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Murine Antibodies
13.2.2. Humanized Antibodies
13.2.3. Chimeric Antibodies
13.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Immunocytokines
13.3.2. Immunoliposome
13.3.3. Radioimmunotherapy
13.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Cancer Monoclonal Antibodies Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Breast Cancer
14.1.2. Blood Cancer
14.1.3. Liver Cancer
14.1.4. Brain cancer
14.1.5. Colorectal Cancer
14.1.6. Others
14.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Murine Antibodies
14.2.2. Humanized Antibodies
14.2.3. Chimeric Antibodies
14.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Immunocytokines
14.3.2. Immunoliposome
14.3.3. Radioimmunotherapy
14.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Cancer Monoclonal Antibodies Market - Opportunity Analysis Index, By Type, By Application, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Cancer Monoclonal Antibodies Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Merck & Co. Inc. (U.S.)
15.2.2. F. Hoffmann-La Roche AG (Switzerland)
15.2.3. Spectrum Pharmaceuticals (U.S.)
15.2.4. Eli Lilly and Company (U.S.)
15.2.5. Amgen Inc. (U.S.)
15.2.6. Bristol-Meyer Squibb (U.S.)
15.2.7. Sanofi (France)
15.2.8. AstraZeneca (U.K.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
